Anthem Blue Cross does not cover stem cell therapy for most of the conditions people ask about, including knee and hip arthritis, tendon and ligament injuries, multiple sclerosis, Parkinson’s disease, Alzheimer’s, ALS, lupus, Crohn’s disease, and other autoimmune or degenerative conditions. Under medical policy TRANS.00035, Anthem classifies these uses, along with platelet-rich plasma, bone marrow aspirate concentrate, and similar regenerative treatments, as investigational and not medically necessary.1Anthem. Stem Cell Therapy, Autologous Cell Therapy, and Related Products The significant exception is hematopoietic stem cell transplantation for certain blood cancers, genetic diseases, and a short list of FDA-approved gene therapies, which Anthem covers when strict clinical criteria are met.
Regenerative Treatments Anthem Denies
If you are considering stem cell therapy through a regenerative medicine clinic or an orthopedic referral, the policy almost certainly rules it out. Anthem’s current policy, updated April 1, 2026, lists the following as investigational for every indication:
- Mesenchymal stem cell therapy for any condition, including osteoarthritis of the knee, hip, or other joints, tendon and ligament injuries, and cartilage defects.
- Autologous cell therapy using skeletal myoblasts, endothelial progenitor cells, or bone marrow mononuclear cells, including for heart damage.
- Platelet-rich plasma injections for soft tissue injuries such as tennis elbow, bone injuries, and wound healing.
- Bone marrow aspirate concentrate for all uses, including critical limb ischemia.
- Autologous blood-derived wound products such as Aurix and Vitagel.
- Autologous protein solutions such as nSTRIDE.
The policy also calls out specific conditions as not covered under any of these treatments: peripheral vascular disease, multiple sclerosis, lupus, Crohn’s disease, celiac disease, COVID-19 pneumonia, Parkinson’s disease, Alzheimer’s disease, and ALS.1Anthem. Stem Cell Therapy, Autologous Cell Therapy, and Related Products
Why These Denials Hold Up
Anthem’s stated reasons for denying regenerative uses include a lack of randomized controlled trials with adequate sample sizes, reliance on preclinical studies and small case series, no standardized scoring methods or long-term follow-up, and unresolved safety concerns about transplanted cells migrating in the body.1Anthem. Stem Cell Therapy, Autologous Cell Therapy, and Related Products The policy also cites recommendations from the American College of Rheumatology and the Arthritis Foundation against stem cell injections for knee or hip osteoarthritis.
The regulatory backdrop reinforces this. According to the FDA, the only approved stem cell products in the United States are blood-forming stem cells from umbilical cord blood, approved solely for disorders of the blood-forming system. No stem cell product is approved for arthritis, chronic pain, neurological conditions, or heart disease, and the FDA has warned that clinics offering unapproved stem cell products outside regulated trials are likely operating illegally.2U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies An appeal of a denial for one of these uses faces both Anthem’s policy and the underlying FDA position.
Stem Cell Treatments Anthem Does Cover
Hematopoietic stem cell transplantation is a separate category of medicine, and Anthem covers it under its own set of medical policies when the clinical criteria for a specific diagnosis are met.
Blood Cancers
Allogeneic transplants (using donor cells) are covered for high-risk or relapsed acute myeloid leukemia, high-risk acute lymphoblastic leukemia in first complete remission or those in second or later remission, chronic myeloid leukemia with specific genetic markers or inadequate treatment response, and chronic lymphocytic leukemia refractory to targeted therapy.3Healthy Blue NC. Hematopoietic Stem Cell Transplantation for Leukemia and Myelodysplastic Syndromes Both allogeneic and autologous transplants are covered for Hodgkin disease and non-Hodgkin lymphoma in patients with primary refractory disease or relapse after initial remission.4Unicare. Hematopoietic Stem Cell Transplantation for Hodgkin Disease and Non-Hodgkin Lymphoma For multiple myeloma, autologous transplants are covered as single, tandem, or repeat procedures, and allogeneic transplants are covered following a prior autologous transplant. Primary amyloidosis and POEMS syndrome also qualify for autologous transplants under specific conditions.5Healthy Blue LA. Hematopoietic Stem Cell Transplantation for Multiple Myeloma and Other Plasma Cell Dyscrasias
Genetic Diseases and Immunodeficiencies
Allogeneic transplants are covered for a defined list of genetic diseases, immunodeficiencies, storage disorders, leukodystrophies, and hemoglobinopathies. Conditions not on the list are classified as investigational, and there is no general exception for rare or life-threatening diseases that fall outside the enumerated criteria.6Wellpoint. Hematopoietic Stem Cell Transplantation for Genetic Diseases and Acquired Anemias
Gene Therapies Delivered Through Stem Cells
Anthem covers two newer categories of FDA-approved gene therapies that use the patient’s own hematopoietic stem cells. Casgevy and Lyfgenia are covered as one-time treatments for sickle cell disease in patients 12 and older who have had at least four severe vaso-occlusive crises in the prior two years, have failed or cannot tolerate hydroxyurea, and lack a suitable donor for a traditional transplant.7Anthem. Gene Therapy for Sickle Cell Disease Casgevy and Zynteglo are covered for transfusion-dependent beta thalassemia patients who meet similar criteria.8Anthem. Gene Therapy for Beta Thalassemia These are managed through Anthem’s dedicated Gene Therapy Solution program.9Anthem. New Gene Therapies Spark Transformative Healthcare Changes
Omisirge
Anthem covers Omisirge (omidubicel), an ex-vivo expanded cord blood product, for patients 12 and older who are candidates for myeloablative allogeneic transplantation for hematologic malignancies. The FDA approved Omisirge in December 2025 for severe aplastic anemia in patients six and older, but Anthem considers that indication investigational, citing a lack of published clinical outcome data.10Anthem. Cellular Therapy Products for Allogeneic Stem Cell Transplantation11U.S. Food and Drug Administration. FDA Approves First Cellular Therapy to Treat Patients With Severe Aplastic Anemia
Where You Can Have the Transplant
A medically necessary transplant still has to be performed at an Anthem-designated Center of Medical Excellence. Qualifying facilities must hold accreditation from the Foundation for the Accreditation of Cellular Therapy, participate in the National Marrow Donor Program, meet minimum annual volume thresholds (at least 10 autologous and 10 allogeneic cases per year for adult programs), and maintain specific survival rate benchmarks.12Anthem Blue Cross. Anthem Center of Medical Excellence Transplant Program Providers are expected to refer patients to an approved facility unless there is a documented medical reason not to.13Anthem. Centers of Medical Excellence Transplant Operations Manual Choosing a hospital outside this network can itself become grounds for denial, so confirm the facility is on Anthem’s list before scheduling.
If Anthem Denies Your Claim
Appeals succeed more often when the underlying treatment is one Anthem’s policies recognize and the question is whether you meet the criteria. Appeals for regenerative treatments the policy flatly classifies as investigational rarely succeed. Either way, the steps are the same:
- Request the denial in writing, with the specific reason, the policy language relied on, and the clinical criteria at issue.
- Work with your physician on a letter of medical necessity, imaging, and documentation of conservative treatments you have already tried and failed.
- File an internal appeal within the deadline stated in the denial letter, attaching clinical literature and your physician’s letter.
- If the internal appeal is denied, request an independent external review. The reviewer is a neutral third party and the decision is binding on the insurer. In California, the Department of Managed Health Care maintains a searchable database of independent medical review decisions.14California Department of Managed Health Care. Independent Medical Review and Complaint Reports
- File a complaint with your state insurance regulator if you believe the denial violates state law.
Litigation is a last resort, but it does happen. In September 2025, a California patient with aggressive multiple sclerosis sued Anthem in Los Angeles County Superior Court (McKay v. Anthem Blue Cross Life and Health Insurance Company, Case No. 25STCV25633), alleging that Anthem denied her hematopoietic stem cell transplant while also denying the prerequisite drugs she needed to meet Anthem’s own criteria. The case remains pending.15EIN Presswire. Gianelli Morris Files Lawsuit Against Anthem Blue Cross Alleging Wrongful Denial of Medically Necessary MS Treatment
Clinical Trials
Under the Affordable Care Act, most commercial plans must cover routine patient care costs for members in qualifying clinical trials.16BMT InfoNet. Insurance and Financial Issues Anthem’s own policy confirms coverage of routine care for participants in federally approved cancer clinical trials, with the trial sponsor covering the investigational drug or procedure and Anthem covering the standard medical services around it.17Anthem Blue Cross. Cancer Clinical Trials For stem cell treatments that remain investigational, a registered trial can be the lowest-cost way to access them.
What You’ll Pay Without Coverage
Costs vary widely by treatment type:
- PRP and bone marrow aspirate injections for joint or soft tissue problems: typically $1,500 to $7,000 per treatment area.18BioInformant. Cost of Stem Cell Therapy
- Adipose tissue or birth-tissue procedures: roughly $4,000 to $12,000 per area.
- Complex or systemic treatments for conditions like MS, diabetes, or neurological disease: often $20,000 to $30,000 or more.18BioInformant. Cost of Stem Cell Therapy
- A full hematopoietic stem cell transplant: can exceed $100,000, and some cases top $500,000.16BMT InfoNet. Insurance and Financial Issues
For a covered transplant with remaining out-of-pocket costs, BMT InfoNet, the Leukemia and Lymphoma Society, the National Marrow Donor Program, and Help Hope Live offer financial assistance that ranges from travel and lodging to fundraising support.19Help Hope Live. Stem Cell Transplant Financial Assistance Most transplant centers also have financial coordinators who can help with pre-authorization and identify resources before treatment begins.16BMT InfoNet. Insurance and Financial Issues